PharmiWeb.com - Global Pharma News & Resources

Clinical trials - Press Releases

Date Title Company
15-Apr-2025 CluePoints’ Technology Named as Finalist in 2025 Citeline Awards CluePoints
15-Apr-2025 Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA HighTide Therapeutics, Inc.
15-Apr-2025 1ST Biotherapeutics Joins The Michael J. Fox Foundation’s LITE Program to Advance LRRK2-Based Parkinson’s Disease Research 1ST Biotherapeutics
14-Apr-2025 New GDP Training with Certificate Pharma Lessons
11-Apr-2025 Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Theriva Biologics
10-Apr-2025 Phastar Secures Finalist Spot at 2025 Citeline Awards Phastar
09-Apr-2025 Microbot Medical® Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY® Endovascular Robotic System Microbot Medical
09-Apr-2025 Ebenbuild Contributes Cutting-Edge Digital Lung Simulations to Pulmonary Fibrosis Drug Development Ebenbuild
08-Apr-2025 Richmond Pharmacology completes first cohort dosing in Hemab Therapeutics Phase1/2 Clinical Trial Investigating HMB-002 for Von Willebrand disease Richmond Pharmacology
03-Apr-2025 Cambridge Cognition selected for two Phase 3 trials combining digital cognitive and voice solutions Cambridge Cognition
03-Apr-2025 Roche provides update on Phase III OCREVUS high dose study in people with relapsing multiple sclerosis Roche
02-Apr-2025 AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease AC Immune
01-Apr-2025 CluePoints Appoints Usama Dar as Chief Product and Technology Officer CluePoints
31-Mar-2025 IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer AstraZeneca
31-Mar-2025 Clinical Trials Market Expands at 6-7% CAGR: Driving Breakthroughs in Medical Research Medi-Tech Insights
31-Mar-2025 Following a planned interim analysis in the PROCEED trial Lundbeck expands the dose finding to intravenous administration of Lu AG09222 in migraine prevention Lundbeck
31-Mar-2025 Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP as first and only BTK inhibitor for 1st-line mantle cell lymphoma AstraZeneca
31-Mar-2025 Imfinzi approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer AstraZeneca
27-Mar-2025 Medidata Launches the Site Insights Program to Elevate the Site Voice for Trials Medidata
27-Mar-2025 Andaman7 Seeks $5m to Continue Investment in Pioneering Technology Andaman7